Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer
NCT ID: NCT06660147
Last Updated: 2024-10-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
327 participants
OBSERVATIONAL
2023-12-11
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer
NCT07022535
Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer
NCT07023484
Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer
NCT00170573
Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT03776812
Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer
NCT00005046
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ARCAGY/ GINECO GROUP
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ICO Paul Papin
Angers, , France
Sainte-Catherine Institut du Cancer Avignon-Provence
Avignon, , France
CHRU Besançon - Hôpital Jean Minjoz
Besançon, , France
Polyclinique Bordeaux Nord
Bordeaux, , France
Centre François Baclesse
Caen, , France
Centre Jean Perrin
Clermont-Ferrand, , France
CHU Grenoble-Alpes - Site Nord (La Tronche)
Grenoble, , France
Centre Hospitalier Départemental de Vendée
La Roche-sur-Yon, , France
Centre Azuréen de Cancérologie
Mougins, , France
Hôpital Privé du Confluent
Nantes, , France
Groupe Hospitalier Diaconesses - Croix Saint-Simon
Paris, , France
Hôpital Cochin
Paris, , France
Hôpital Européen Georges Pompidou
Paris, , France
Institut Curie
Paris, , France
Clinique Francheville
Périgueux, , France
HCL - Centre Hospitalier Lyon Sud
Pierre-Bénite, , France
CHU de Poitiers - Hôpital de la Milétrie
Poitiers, , France
Centre Eugène Marquis
Rennes, , France
ICO - Centre René Gauducheau
Saint-Herblain, , France
Oncopole Claudius Regaud - IUCT Oncopole
Toulouse, , France
Clinique Pasteur
Toulouse, , France
ICL - Centre Alexis Vautrin
Vandœuvre-lès-Nancy, , France
Gustave Roussy
Villejuif, , France
Centre Hospitalier Princesse Grace
Monaco, , Monaco
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GINECO OV131
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.